HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
HARVARD BIOSCIENCE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $36.62M
- P/E (TTM)
- –
- Dividend yield
- –
HARVARD BIOSCIENCE INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instruments, Equipment, Software, and Accessories [Member] | $78.26M | $86.96M | $105.72M | $108.17M | $114.12M | $97.47M | $110.22M | $115.07M | – | – | 90.4% | -10.0% |
| Service, Maintenance, and Warranty Contracts [Member] | $8.29M | $7.17M | $6.53M | $5.17M | $4.79M | $4.63M | $5.96M | $5.71M | $2.79M | – | 9.6% | +15.6% |
| Instruments, equipment software and accessories [Member] | – | – | – | – | – | – | – | $115.07M | $74.62M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $38.97M | $41.74M | $48.21M | $49.91M | $49.83M | $42.05M | $82.94M | $84.05M | $41.72M | $65.18M | 45.0% | -6.6% |
| EMEA [Member] | $26.71M | $28.41M | $33.28M | – | – | – | – | – | – | – | 30.9% | -6.0% |
| China | $10.97M | $13.30M | – | – | $24.82M | $23.88M | – | – | – | – | 12.7% | -17.5% |
| Asia, Other [Member] | $6.68M | $7.10M | $8.77M | – | – | – | – | – | – | – | 7.7% | -5.9% |
| Americas, Other [Member] | $3.23M | $3.60M | $3.52M | – | – | – | – | – | – | – | 3.7% | -10.3% |
| Rest of the World [Member] | – | – | $12.76M | $16.34M | $19.81M | $6.22M | $8.14M | $8.64M | $9.48M | $9.44M | – | – |
| United Kingdom | – | – | – | – | – | – | $116.18M | $14.52M | $15.04M | $16.42M | – | – |
| Total [Member] | – | – | – | – | – | – | – | – | $101.88M | $104.52M | – | – |
| Germany | – | – | – | – | – | – | $13.67M | $13.56M | $11.16M | $13.48M | – | – |
| Rest Of The World [Member] | – | – | – | – | – | – | – | $8.64M | $9.48M | – | – | – |
| Europe [Member] | – | – | $32.80M | $30.69M | $35.77M | $29.94M | – | – | – | – | – | – |
| Greater China [Member] | – | $13.30M | $18.49M | $16.39M | $13.50M | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Harvard Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.